SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the “Company” or “Ligand”) today announced that it has earned from Wyeth (NYSE:WYE) a milestone payment of $250,000 as a result of Wyeth’s submission on September 5, 2007, of a Market Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market bazedoxifene for the prevention and treatment of osteoporosis.
